Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 47
Healthy volunteers: no

Brief summary:
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days. This study determined how long the drug stays in the body and how it affects blood sugar levels. After screening, the study lasted about 2 months for each participant. Participants continued their prestudy regimen of diet and exercise alone or in combination with metformin.

Detailed description:

Arms:
arm 1: Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days. arm 2: Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days. arm 3: Participants received 10 mg LY2405319 injected SC once daily for 28 days. arm 4: Participants received 20 mg LY2405319 injected SC once daily for 28 days.

Interventions: intervention 1: LY2405319 intervention 2: Placebo
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered SC

Protocol document: